Dianthus Therapeutics, Inc. $DNTH Shares Sold by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC reduced its stake in Dianthus Therapeutics by 60.2%, selling 32,948 shares during the first quarter, leaving them with 21,818 shares valued at approximately $396,000.
• Dianthus Therapeutics reported a quarterly EPS of ($0.88), missing estimates, with revenue of $0.19 million compared to anticipated revenue of $0.87 million.
• Analysts give Dianthus Therapeutics a consensus rating of "Buy" with an average price target of $60.67, indicating positive future expectations for the stock.

Cubist Systematic Strategies LLC cut its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 60.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,818 shares of the company's stock after selling 32,948 shares during the period. Cubist Systematic Strategies LLC owned 0.07% of Dianthus Therapeutics worth $396,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DNTH. US Bancorp DE boosted its stake in shares of Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after purchasing an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $59,000. GAMMA Investing LLC boosted its stake in Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after acquiring an additional 3,758 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Dianthus Therapeutics by 21.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock valued at $207,000 after acquiring an additional 1,647 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Dianthus Therapeutics by 38.7% in the first quarter. Invesco Ltd. now owns 15,978 shares of the company's stock valued at $290,000 after acquiring an additional 4,457 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Insider Activity at Dianthus Therapeutics

In related news, CFO Ryan Savitz sold 20,000 shares of the business's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.15% of the stock is owned by corporate insiders.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded down $0.70 during trading on Friday, hitting $37.16. 996,987 shares of the company's stock were exchanged, compared to its average volume of 912,657. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -11.43 and a beta of 1.46. The business has a 50-day simple moving average of $23.01 and a 200-day simple moving average of $20.53. Dianthus Therapeutics, Inc. has a 52-week low of $13.36 and a 52-week high of $38.59.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on DNTH shares. Raymond James Financial restated an "outperform" rating and issued a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday. Robert W. Baird raised their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an "outperform" rating in a research note on Tuesday. Wedbush raised their target price on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the company an "outperform" rating in a research note on Friday. Stifel Nicolaus raised their target price on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a "buy" rating in a research note on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, September 8th. Nine analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $61.57.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.